The customary approach to early-phase clinical trial design, where the focus is on identification of the maximum tolerated dose, is not always suitable for noncytotoxic or other targeted therapies.
Bayesian inference provides a robust framework for combining prior knowledge with new evidence to update beliefs about uncertain quantities. In the context of statistical inverse problems, this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results